Показано 0 из 0
Дата |
---|
17.05.2024 |
16.05.2024 |
15.05.2024 |
14.05.2024 |
13.05.2024 |
10.05.2024 |
09.05.2024 |
08.05.2024 |
07.05.2024 |
06.05.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
0.98
|
1.14
|
1.05
|
0.90
|
1.05
|
1.015
|
|
|
967.16
|
10.00
|
0.96
|
1.18
|
1.05
|
1.05
|
1.05
|
1.05
|
|
|
56.00
|
5.00
|
1.01
|
1.20
|
1.11
|
1.07
|
1.11
|
1.08
|
|
|
386.60
|
6.00
|
0.97
|
1.08
|
1.10
|
1.045
|
1.10
|
1.045
|
|
|
60.45
|
4.00
|
0.99
|
1.15
|
1.11
|
1.07
|
1.11
|
1.07
|
|
|
352.61
|
7.00
|
1.04
|
1.18
|
1.10
|
1.08
|
1.10
|
1.08
|
|
|
660.00
|
4.00
|
0.96
|
1.10
|
1.08
|
1.07
|
1.08
|
1.07
|
|
|
24.84
|
3.00
|
1.01
|
1.10
|
1.08
|
1.08
|
1.08
|
1.08
|
|
|
|
1.00
|
0.96
|
1.10
|
1.07
|
1.00
|
1.08
|
1.08
|
|
|
1 278.50
|
15.00
|
0.96
|
1.07
|
1.07
|
1.01
|
1.07
|
1.05
|
|
|
1 113.73
|
23.00
|
Estrella Immunopharma, Inc. operates as a preclinical-stage biopharmaceutical company. The Company focuses on developing CD19 and CD22-targeted T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella Immunopharma serves customers worldwide.